221800 — U2Bio Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for U2Bio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	50,553	69,013	30,792	25,040	25,593
Cost of Revenue
Gross Profit	16,318	26,639	8,219	5,039	5,394
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	41,525	53,327	32,174	28,153	27,988
Operating Profit	9,027	15,686	-1,382	-3,113	-2,395
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,602	16,066	38.2	-1,620	-1,323
Provision for Income Taxes
Net Income After Taxes	9,236	13,160	646	-2,840	-1,642
Net Income Before Extraordinary Items
Net Income	9,236	13,160	646	-2,840	-1,642
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,236	13,160	646	-2,840	-1,642
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,065	1,310	65	-252	-139
Dividends per Share